Karnofsky performance status >= 60
ECOG performance status =< 2 (Karnofsky >= 60 %)
Karnofsky performance status >= 60 within 21 days prior to study entry
Karnofsky performance status of 70-100%
ECOG performance status ?1 (Karnofsky ?70%).
Patients must have a Karnofsky performance status of >= 60
Karnofsky performance status >= 70%.
Karnofsky performance status >= 70
Karnofsky performance ? 70%
Karnofsky performance status >= 60
Karnofsky Performance Status 70 or greater.
Karnofsky performance status >= 60
Karnofsky performance status < 30
Karnofsky performance status >= 70
Karnofsky performance status > 50%
Karnofsky Performance Status <70
Karnofsky performance status ? 60%
Karnofsky performance status of at least 70
Karnofsky performance status >= 60%
Karnofsky performance status >= 70%
Karnofsky performance status >= 60
ECOG performance status ?2 (Karnofsky ?60% )
Karnofsky performance status > 60
Karnofsky performance status >= 70%
Karnofsky performance status >= 80%
Patients must have a Karnofsky (adult) or performance status >= 70%.
INCLUSION - ENROLLMENT: Karnofsky performance status 50% to 100%
Karnofsky performance status of 70 or higher.
Karnofsky performance status >= 70 %
Karnofsky performance status of 70 or higher
For cohort 4, (glioblastoma), patients must have Karnofsky performance status of >= 60
Karnofsky Performance status of ? 70%
Karnofsky performance status of >= 60
Karnofsky performance status of 70-100%
Patients must have a Karnofsky performance status >= 70
Karnofsky performance status of >= 70%
ECOG performance status of 0–1 (Karnofsky >= 80%)
Karnofsky performance status ? 80%
Karnofsky performance status >= 60
Patients must have a Karnofsky performance status of >= 60%
Patients must have a Karnofsky performance status of ? 60%
Karnofsky performance status >= 60 within 7 days prior to registration
Karnofsky Performance Status >= 60%
Karnofsky performance status >= 70
Patient must have a Karnofsky performance status ?70%.
Karnofsky performance status of 70 or higher
Karnofsky performance status >= 50%
Karnofsky performance status ? 70%.
ECOG performance status 0-1 (Karnofsky >= 80%)
Karnofsky performance status >= 60%
Karnofsky performance status < 70
Karnofsky Performance Status >= 60%
An ECOG Performance Status of 0 to 1 and Karnofsky Performance Status of 80 - 100
Karnofsky performance status of 60% or better
Patients must exhibit a Karnofsky performance status of >= 70
Karnofsky performance status < 70
Karnofsky performance status > 60%
Karnofsky performance status >= 60%
Karnofsky performance status >= 70%
Karnofsky performance status >= 60%
Patients must have a Karnofsky performance status of >= 70
Karnofsky performance status >= 60%
Karnofsky performance status of >= 70
Must have a Karnofsky performance status of 70-100
Karnofsky performance status >= 70%
Karnofsky performance status >= 70
Karnofsky performance status of 70-100 %
Karnofsky performance status >= 60%
Karnofsky performance status >= 70
Karnofsky performance status > 70%
Patients must have Karnofsky performance status >= 70%
Karnofsky performance status of >= 70
Karnofsky performance status >= 70
Karnofsky performance status >= 60%
Karnofsky performance status > 60%
Karnofsky performance status > 70%
Karnofsky performance status of >= 70%
Karnofsky performance status >= 70
Karnofsky performance status ? 70%.
Karnofsky performance status >= 60%
Karnofsky performance status >= 70%
INCLUSION CRITERIA FOR TNBC: Karnofsky performance status of >= 70%
Karnofsky performance status 70% or above
Karnofsky performance status >= 60%
Karnofsky performance status of >= 80
Karnofsky performance status >= 70%
Karnofsky performance status of 70-100%
Karnofsky performance status >= 70%
Karnofsky performance status of >= 70%
ECOG performance status > 2 (Karnofsky < 60%)
Karnofsky performance status 70-100
Karnofsky performance status >= 60
Karnofsky status >= 70%
Karnofsky performance status of 70 or above
Karnofsky performance status 70 or greater
Performance status: Karnofsky >= 70%
Karnofsky performance status >= 70%
Karnofsky performance status >= 70
Karnofsky performance status >= 70% =< 2
Karnofsky performance status of at least 70%
Patients with Karnofsky performance status of >= 70
Karnofsky performance status of 70-100%
Karnofsky performance status >= 50%
Karnofsky performance status >= 60%
Karnofsky performance status >= 50%
Karnofsky performance status of >= 60%
Karnofsky performance status >= 70%
ECOG performance status < 2 (Karnofsky > 60%).
Karnofsky performance status 50-100%
Patients must have a Karnofsky performance status of >= 60
Karnofsky performance status >= 60
Karnofsky status >= 70%
Patients must have a Karnofsky performance status of >= 60
Karnofsky performance status >= 70
Karnofsky performance status >= 60
Have a Karnofsky performance status of ?70.
Karnofsky performance status 60-100
Karnofsky performance status >= 80%
A life expectancy of at least 6 months with a Karnofsky performance status of at least 70
Karnofsky performance status >= 70
Karnofsky performance status >= 70
Patients must have a Karnofsky performance status of > 70
Patients must have a Karnofsky Performance Status of >= 60
Patients must have a Karnofsky Performance Status of >= 60
Karnofsky performance status of 60-100
Karnofsky performance status >= 70%
Karnofsky performance status < 70
Karnofsky status of >= 60%
Karnofsky performance status ? 60%.
Karnofsky performance status ? 70%.
Karnofsky performance status >= 60% within 4 weeks prior to start of any therapy
Karnofsky performance status ? 60%
Karnofsky performance status ? 60%
Karnofsky Performance Status at least 60%
Karnofsky Performance Status ? 70%
Karnofsky performance status of > 60.
ECOG performance status ? 2 (Karnofsky ? 60%)
Karnofsky performance status >= 70.
Karnofsky performance status >= 60%
Karnofsky performance status >= 60%
Patients must have a Karnofsky performance >= 60%
Karnofsky performance status >= 70
Karnofsky performance status 50% to 100%
Karnofsky performance status >= 70%
Karnofsky performance status ? 70 %
TUMOR BIOPSY SEQUENCING: Karnofsky performance status >= 70%
TREATMENT: Karnofsky performance status >= 70%
Karnofsky performance status >= 70
Karnofsky performance status of 70 or higher
Karnofsky performance status >= 50
DONOR: Karnofsky performance status of >= 70% defined by institutional standards
Karnofsky performance status >= 70
Secondary Registration: Karnofsky performance status >= 70
Karnofsky performance status >= 70
Karnofsky performance status >= 70%
DONOR: Karnofsky performance status of >= 70% defined by institutional standards
Patients must have a Karnofsky performance status of >= 60
Karnofsky performance status >= 70%
Karnofsky performance status > 70%
Karnofsky performance status >= 60
Karnofsky performance status >= 60%
Karnofsky performance status >= 70%
Patient has a Karnofsky performance status of >= 70%
Karnofsky performance status >= 70%
Karnofsky performance status >= 70%
Karnofsky performance status >= 50%
Karnofsky performance status >= 70
Karnofsky performance status: > 80% (> 60% if poor performance status is related to lymphoma)
Karnofsky performance status ? 60 (Appendix 1).
Karnofsky performance status >= 70%
Karnofsky performance status of ? 60
Karnofsky performance status ? 70%.
Karnofsky performance status >= 60%
Karnofsky performance status <70%
Karnofsky performance status >= 60%
Karnofsky performance status of 70 or higher
Karnofsky performance status >= 70 within 7 days prior to registration
Karnofsky performance status >= 50 %
Karnofsky performance status > 70
Karnofsky performance status less than 80% within 60 days prior to study
Karnofsky performance status > 70
Karnofsky performance status of >= 50
ECOG performance status =< 2 (Karnofsky >= 60%)
Karnofsky performance status >= 70
Karnofsky performance status >= 60%
Karnofsky performance status >= 70%
Karnofsky performance status >= 70
Karnofsky performance status >= 70 %
Karnofsky performance status > 70
Karnofsky performance status >= 70%
Karnofsky performance status < 70%
Karnofsky Performance Status ? 70% within 28 days prior to registration for protocol therapy.
ECOG performance status of 0-2, Karnofsky Performance Status ?60 (for glioma subjects).
Karnofsky performance status 70-100
Karnofsky performance status of >= 70
Karnofsky performance status >= 70%
Karnofsky performance status ?60.
Patients must have a Karnofsky performance status >= 70
Karnofsky performance status 70 or greater
COHORT A: The subject must have Karnofsky performance status of 80-100
COHORT B: The subject must have Karnofsky performance status of 80-100
Karnofsky performance status >= 70%
Karnofsky performance status of 60% or better
Karnofsky performance status >= 60%
Karnofsky performance status >= 60%
Karnofsky performance status >= 70%
Karnofsky performance status >= 70
Patients must have a Karnofsky performance status of >= 60
Karnofsky performance status >= 60%
Karnofsky performance status >= 70%
Karnofsky performance status >= 60%
Karnofsky performance status =< 70
Karnofsky Performance Status >= 70%
Karnofsky performance status of ?70.
Karnofsky performance status ? 70%
Karnofsky performance Status ? 70%
Karnofsky performance status >= 70%
Karnofsky performance status >= 70
Patients must have a Karnofsky (adults) or performance status >= 70%
Karnofsky performance status >= 60 within 14 days prior to registration
Karnofsky performance status of >= 80-100
Karnofsky performance status >= 60%
Karnofsky performance status 80 or better
Karnofsky performance status >= 60%
Patients must have a life expectancy of >= 3 months and a Karnofsky performance status >= 60
Performance status - Karnofsky >= 60%
Karnofsky performance status >= 70%
Karnofsky performance status > 70%
Karnofsky Performance Status ? 70
Patients must have a Karnofsky performance status of >/= 60.
Karnofsky performance status > 70
Karnofsky performance status < 70
Karnofsky performance status >= 70
Karnofsky performance status of >= 60%
Karnofsky performance status >= 70 %
Karnofsky performance status > 50%
Patients must have a Karnofsky performance status of >= 60
Karnofsky performance status > = 70%
Patients must have a Karnofsky (adult) or performance status >= 70%
Karnofsky performance status >= 70%
Karnofsky performance status ? 80
Karnofsky performance status < 70
Karnofsky performance status >= 70
Karnofsky performance status ? 70
Karnofsky performance status >= 60%
Karnofsky performance status >= 60%
Karnofsky performance status at time of study entry must be >= 70%
Karnofsky performance status ?70%
Karnofsky performance status < 50%
Karnofsky performance status >= 70%
Patients must have a Karnofsky performance status >= 70%
Karnofsky performance status >= 80%
Performance status >= 80% (Karnofsky)
Performance status of < 80% (Karnofsky)
Karnofsky performance status (PS) >= 40
Karnofsky performance status >= 60%
Karnofsky performance status > 60
Karnofsky performance status >= 80%
Karnofsky performance status of 70 to 100
Karnofsky performance status >= 60%
Karnofsky performance status >= 70%
Karnofsky performance status >= 70%
Karnofsky performance status >= 70%
Karnofsky performance status >= 70%
Karnofsky performance status > 60
Karnofsky performance status >= 50
Karnofsky Performance Status 70 or above.
Does the subject have a Karnofsky performance status ? 70?
Meet Karnofsky performance status requirements
Karnofsky performance status of at least 60%
Karnofsky Performance ? 70%
Karnofsky performance status >= 60%
70 or above on Karnofsky Performance Status
Karnofsky performance status >= 60%
ECOG performance status ?1 or Karnofsky ?70%.
Cohort A: Karnofsky performance status >= 70%
The subject has a Karnofsky performance status of > 70%
Karnofsky performance status >= 70
Karnofsky performance status >= 70
Patient has Karnofsky performance status >= 60
Karnofsky performance status >= 70%
Karnofsky performance status of > 60%
Karnofsky performance status >= 60
Performance status must be Karnofsky 50-100%
Karnofsky performance status >= 70%
Karnofsky Performance Status ? 70
Patients must have a Karnofsky performance status of > 60
Patients must have a Karnofsky performance status of >= 60
Karnofsky status of >= 70%
Physical exam and Karnofsky performance status
Karnofsky performance status >= 60%
Karnofsky performance status >= 30%.
Karnofsky performance status >= 60
Patients must have a Karnofsky performance status of > 70
Karnofsky performance status ? 70 within 14 days prior to registration
Karnofsky performance status more than 60
Karnofsky performance status >= 50%
Karnofsky performance status >= 70%
Karnofsky performance status > 60%
Karnofsky performance status >= 50%
Karnofsky performance status >= 80%
Patients with Karnofsky performance status < 80%
Performance status: Karnofsky >= 70%
Have a Karnofsky performance rating of 60 or greater
Karnofsky performance status >= 50%
No need for Karnofsky performance status
Karnofsky performance status >= 80%
Karnofsky performance status >= 60
DONOR: Karnofsky performance status of >= 70% defined by institutional standards
Karnofsky performance status > 60
Karnofsky performance status < 30
Karnofsky performance status >= 50%
Karnofsky performance status >= 50%
Karnofsky performance status >= 50
Karnofsky performance status >= 40%
Karnofsky performance status < 30
Karnofsky performance status > 60
Karnofsky performance status of less than 70% within the last 60 days prior to study
Have Karnofsky performance status >= 60
Individuals with a Karnofsky performance status of at least 80%
Karnofsky performance status >= 70%
Performance status: Karnofsky performance status score >= 80%
Karnofsky performance status >= 70%
Karnofsky performance status >= 70%
Karnofsky performance status ? 70%
ECOG performance status ? 2 and Karnofsky ? 60%
Karnofsky performance status >= 70%
Karnofsky Performance Status ? 70
Karnofsky performance Status ? 70% (Section 15)
Karnofsky performance status >= 60
Karnofsky performance status > 60
Karnofsky performance status > 70%
Karnofsky performance status > 70%
Karnofsky performance status < 70%
Karnofsky performance status >= 60%
Karnofsky performance status (PS) >= 70
Karnofsky performance status of < 60
Karnofsky performance status >= 70%
ECOG performance status =< 2 (Karnofsky >= 60%)
Karnofsky performance status >= 60%
Karnofsky performance status >= 70
Karnofsky performance status > 70%
Karnofsky performance status < 70%
Karnofsky performance status >= 70
Karnofsky performance status >= 70
Karnofsky performance status of >= 60
Karnofsky performance of 60% or greater
Karnofsky performance status >= 70
Karnofsky performance status >= 70
Karnofsky performance status of < 60
ECOG performance status of 0-2 (or a Karnofsky performance status of >50%)
Karnofsky Performance Status of <60%.
Karnofsky performance status (KPS) >= 60%
Karnofsky Performance Status (KPS) rating of >/=70 at baseline;
Patients must have a Karnofsky performance status (KPS) >= 60
Must have an ECOG performance status of 0 - 2, or KPS ? 60.
Karnofsky performance status (KPS) >= 70
Patients must have a KPS performance status of >= 60
Karnofsky Performance Status (KPS) of ?70
Karnofsky performance status (KPS) of at least 60%.
Karnofsky performance status (KPS) ? 70
Karnofsky performance status (KPS) >= 70%
Patients must have a Karnofsky performance status (KPS) >= 60
Patient has a Karnofsky performance status (KPS) ? 70.
Karnofsky performance status (KPS) >= 70 within two weeks of enrollment
Karnofsky performance status (KPS) >= 50
Karnofsky performance status (KPS) of greater than or equal to 70
Karnofsky performance status (KPS) ? 60
Karnofsky performance status (KPS) >= 70%
Karnofsky score >= 70% (inpatient leukemia service transfers without discharge are acceptable provided patient has equivalent Karnofsky performance status [KPS] as if were outpatient).
Karnofsky performance status (KPS) >= 60%
Must have a Karnofsky Performance Status (KPS) >= 70 at assessment <= 14 days prior to randomization (N/A to the sub-study).
Karnofsky performance status (KPS) >= 70
Karnofsky performance status (KPS) >= 60
Karnofsky performance status (KPS) >= 60
Karnofsky performance status (KPS) >= 60
Karnofsky performance status (KPS) < 60
Karnofsky performance status (KPS) < 70
Karnofsky performance score (KPS) >= 70%
ECOG performance status of 0 or 1 (51), or KPS of 100% to 80% (52)
Karnofsky performance status (KPS) >= 80
Karnofsky performance status (KPS) of at least 70%
Karnofsky performance status (KPS) of >= 80% on the modified KPS tool
Patients must have a Karnofsky performance score (KPS) > 60.
Have a Karnofsky performance score (KPS) >= 60
Karnofsky performance status (KPS) >= 70
Have a Karnofsky performance status (KPS) >= 70
Karnofsky performance status (KPS) performance status of 60% or greater
Karnofsky performance score (KPS) >= 70%
Karnofsky performance status (KPS) >= 60
Karnofsky performance status (KPS) >= 70
Karnofsky performance status (KPS) >= 70
Patients must exhibit a Karnofsky performance status (KPS) >= 70
Karnofsky Performance Status (KPS) ? 60%.
Patients must have Karnofsky Performance Status (KPS) > 60% (i.e., 70, 80, 90 or 100).
Karnofsky performance status (KPS) of at least 60%
Patients should have a Karnofsky performance status (KPS) greater than or equal to 70%
Karnofsky performance status (KPS) >= 70
Have a performance status of >= 60 on the Karnofsky performance status (KPS)
Karnofsky Performance Status (KPS) ? 70%
Karnofsky Performance Status (KPS) >= 70
Karnofsky performance status (KPS) >= 90% patients older than 70 years, KPS >= 80% patients younger than 70 years
Karnofsky performance status (KPS) of >= 70%
Karnofsky performance status (KPS) < 60%
Karnofsky performance status (KPS) >= 60
Karnofsky performance status (KPS) >= 70%
Karnofsky performance status (KPS) >= 70
Karnofsky performance status (KPS) >= 60%
Karnofsky performance status (KPS) >= 60%
Karnofsky performance status (KPS) of >= 70
Karnofsky performance status (KPS) of >= 70%
Karnofsky performance status (KPS) of >= 70%
Karnofsky performance status score (KPS) of >= 60
Karnofsky performance status (KPS) >= 70%
Karnofsky performance status (KPS) >= 60
Karnofsky performance status (KPS) of >= 70%
Karnofsky performance status (KPS) >= 60
Patient with Karnofsky performance status (KPS) equal to or greater than 40
Patients with Karnofsky performance status (KPS) less than 40
Karnofsky performance status (KPS) score >= 70
Karnofsky performance status (KPS) >= 60
Karnofsky performance status (KPS) of greater than or equal to 60
Performance status evaluated by Eastern Cooperative Oncology Group (ECOG) or Karnofsky performance scales (KPS) patients must have a score of 0-II (ECOG) or >= 70% (KPS)
Karnofsky Performance Status (KPS) <50%
Karnofsky performance score (KPS) ? 70%
Karnofsky Performance Status (KPS) of >/=70%.
Karnofsky performance status (KPS) >= 80% within 7 days prior to registration for protocol therapy
Participant has a Karnofsky performance status (KPS) of 70 or higher.
Karnofsky performance score (KPS) >= 70
Karnofsky performance status (KPS) performance status of 60% or greater
Participants must have a Karnofsky performance status (KPS) >= 60
Karnofsky performance status (KPS) >= 70%
RPA class III (Karnofsky performance status [KPS] < 70%)
Karnofsky performance status (KPS) of >= 70%
Karnofsky performance status (KPS) >= 70
Karnofsky performance status (KPS) >= 70
Karnofsky performance status (KPS) >= 80
Karnofsky performance status equal to 50 or higher, with the following exception\r\n* Patients with Karnofsky performance status (KPS) 30 to 50 are eligible if the reason for the poor performance status is neurologic deficit from primary central nervous system (CNS) lymphoma; (patients with KPS 30 to 50 due to reasons other than primary CNS lymphoma are ineligible; patients with KPS under 30 for any reason are ineligible)
Karnofsky performance status of 70% or greater; lower Karnofsky performance status (KPS) down to 50% may be acceptable if the restriction of activity is solely due to intractable pain from myeloma lesions
Karnofsky performance status (KPS) >=70
ECOG performance score >= 3 (Karnofsky performance status [KPS] < 50%)
Karnofsky Performance Status (KPS) of at least 70% for Cohort 1, 2, and 3; KPS of 50-60% for Cohort 4
Karnofsky performance status (KPS) >= 70%
Karnofsky Performance Score (KPS) ? 70%
Has Karnofsky Performance Status (KPS) ?70%, as assessed within 10 days prior to treatment allocation.
Has Karnofsky performance status (KPS) ? 70% as assessed within 10 days prior to randomization.
Karnofsky performance status (KPS) >= 70
Karnofsky Performance Status (KPS) score at least 70%.
Karnofsky Performance Status (KPS) greater than or equal to (>=) 70%.
Karnofsky performance status (KPS) >=70%
Karnofsky performance status (KPS) >= 60%
Karnofsky performance status (KPS) >= 60%
Participants must have a Karnofsky Performance Status (KPS) >= 60
Eastern Cooperative Group Performance (ECOG) or Karnofsky Performance Status (KPS) of 0-1 or >= 80%, respectively; if KPS is decreased due to myeloma, >= 70% is acceptable
Patients must have a Karnofsky performance status (KPS; Appendix D) of ? 70%
Karnofsky performance status (KPS) >= 60
Karnofsky performance status (KPS) of > 80%
Have a Karnofsky performance status (KPS) >= 70
Participants must have a Karnofsky performance status (KPS) of >= 50
Karnofsky performance status (KPS) performance score >= 70%
Karnofsky Performance Status (KPS) of at least 70%
Subjects must have a Karnofsky performance status (KPS) of >= 70%
Karnofsky performance status (KPS) 70-100%
Karnofsky performance status (KPS) of >= 70% at time of enrollment
Karnofsky Performance Score (KPS) of ? 70%
Patients must have a Karnofsky performance status (KPS) > 60
Karnofsky performance status of >= 80% on the modified Karnofsky performance status (KPS) tool
Karnofsky performance status (KPS) 70-100
Karnofsky performance status (KPS) >= 60
Karnofsky performance score (KPS) >= 70%
Patients must have a Karnofsky performance score (KPS) of >= 60
Karnofsky performance status (KPS) >= 60%
All patients must have a Karnofsky performance status (KPS) >= 70
Karnofsky performance status (KPS) >= 70%
Karnofsky performance status (KPS) >= 80%
Karnofsky performance score (KPS) >= 60%
Karnofsky Performance Score (KPS)>=60.
The patient must have a Karnofsky performance score (KPS) of >= 70% at the time of entry
Karnofsky Performance Status (KPS) ?80%
Patients must have a Karnofsky performance status (KPS) of >= 60
Karnofsky performance score (KPS) < 70%
Karnofsky performance status (KPS) >= 60
Karnofsky performance status (KPS) >= 70
Karnofsky performance status (KPS) >= 70%
Karnofsky performance status (KPS) >= 80%
Karnofsky Performance Status (KPS) of ?70
Karnofsky performance status (KPS) >= 70%
Karnofsky performance score (KPS) >= 70%
Karnofsky performance status (KPS) greater than or equals to 70
The patient must have a Karnofsky performance status (KPS) of >= 80%
Karnofsky performance status (KPS) > 70%
Karnofsky performance status (KPS) >= 70%
Karnofsky Performance Status (KPS) > 50%
Karnofsky performance status (KPS) < 70
Karnofsky performance status (KPS) 0-2
Subject has a Karnofsky performance status (KPS) ? 70%.
Karnofsky performance status (KPS) score >= 70
Have a Karnofsky Performance Score (KPS) equal to or greater than 70
Karnofsky Performance Score (KPS) ? 70%.
Karnofsky Performance Status (KPS) score ? 70
Karnofsky performance status (KPS) >= 70%
Karnofsky performance status (KPS) >= 50
Karnofsky performance status (KPS) score >= 40
Karnofsky performance status (KPS) >= 70%
Karnofsky performance status (KPS) score ? 70%.
Patient has Karnofsky performance status (KPS) ?70%.
Karnofsky performance status (KPS) >= 60
Karnofsky performance status (KPS) of >= 60% at study entry
Karnofsky performance status (KPS) of >= 70%
Karnofsky performance status (KPS) of >= 70%
Karnofsky Performance Score (KPS) ? 70%
Karnofsky performance status (KPS) > 70
Performance status KPS 70 or more.
Karnofsky performance status (KPS) >= 70 %
Karnofsky performance status score (KPS) >= 60
Karnofsky performance status (KPS) >= 60
Karnofsky performance status (KPS) >= 60%
PATIENT ONLY: Karnofsky performance status (KPS) of 80 or above
Karnofsky performance status (KPS) greater than 60.
PATIENTS ONLY: Karnofsky performance status (KPS) of 80 or above
Karnofsky performance status (KPS) >= 60%
Have a Karnofsky performance status (KPS) score of 60% (be able to care for most of the personal needs)
Karnofsky performance score (KPS) >= 70%
Karnofsky performance status (KPS) performance status of 60% or greater
Karnofsky performance status (KPS) >= 60
Karnofsky performance status (KPS) >= 70
Karnofsky Performance Status (KPS) ? 70%
Karnofsky performance status (KPS) >= 70%
Group I: Karnofsky performance score (KPS) >= 80
Group II: Karnofsky performance score (KPS) >= 80
Group III: Karnofsky performance score (KPS) >= 80
Patient must have Karnofsky performance status (KPS) of at least 60
Karnofsky Performance Status (KPS) >= 70
Karnofsky performance status (KPS) score >= 60
Karnofsky Performance Status (KPS) score ? 70%
Lansky >= 50% for patients =< 10 years of age or Karnofsky >= 50% for patients > 10 years of age
Karnofsky >= 50% for patients > 10 years of age
Adequate performance status: Karnofsky ? 50 for patients ? 16 years of age
Adequate performance status: Lansky ? 50 for patients < 16 years of age
Subjects > 10 years of age: Karnofsky >= 50%; Subjects =< 10 years of age: Lansky scale >= 50%
Patients must have a Lansky or Karnofsky performance status score of >= 50; use Karnofsky for patients > 16 years of age and Lansky for patients =< 16 years of age
Subjects must have a performance status of > 50%; use Karnofsky for patients > 16 years of age and Lansky for patients =< 16 years of age
Karnofsky ? 50 for patients ? 16 years of age, and Lansky ? 50 for patients < 16 years of age.
Karnofsky > 50 for patients > 16 years of age and Lansky > 50 for patients =< 16 years of age
Karnofsky performance status >= 50% for patients > 16 years of age, or Lansky performance status >= 50% for patients =< 16 years of age.
Patient must have Karnofsky >= 60% for patients > 10 years of age; Lansky Play Scale >= 60 for children =< 10 years of age
Patients must have a performance status of 0, 1 or 2; use Karnofsky >= 60 for patients > 16 years of age and Lansky >= 60 for patients =< 16 years of age
Performance status: Karnofsky >= 50 for patients > 16 years of age; Lansky >= 50 for patients =< 16 years of age
Karnofsky performance status >= 50 for patients >= 16 years of age and a Lansky performance status >= 50 for patients aged < 16 years
Patients must have a performance status of >= 70; (Karnofsky if > 16 years and Lansky if =< 16 years of age)
Karnofsky ? 50% for patients > 16 years of age and Lansky ? 50 for patients ? 16 years of age.
Patients must have a performance status of >= 70; (Karnofsky if > 16 years and Lansky if =< 16 years of age
Patients must have a Lansky performance status of >= 30 for children =< 10 years of age or a Karnofsky performance status of > 30 for children > 10 years of age
Patients must have a performance status of >= 70; (Karnofsky if > 16 years and Lansky if < 16 years of age)
Performance status: Karnofsky >= 80% (subjects >= 16 years of age); Lansky >= 80% (for subjects 10-15 years of age)
Performance level: Lansky ? 50% for patients ? 16 years of age and Karnofsky ? 50% for patients > 16 years of age.
Performance status greater than or equal to (>=) 70 by Lansky scale (for participants less than [<] 16 years of age) or Karnofsky scale (for participants [>=] 16 years of age)
PRE-REGISTRATION: Performance level as measured by Karnofsky >= 60% for patients > 16 years of age or Lansky >= 60% for patients =< 16 years of age.
ENROLLMENT: Performance level as measured by Karnofsky >= 60% for patients > 16 years of age or Lansky >= 60% for patients =< 16 years of age.
Patients must have a Lansky or Karnofsky performance status score of >= 70; Karnofsky system will be used for patients > 16 years of age and Lansky system for patients < 16 years of age
Patients must have a Karnofsky performance level of >= 30 for patients > 16 years of age or a Lansky performance scale of >= 30 for patients =< 16 years of age and life expectancy > 8 weeks
Performance status - Karnofsky >= 60 (16 years and older) or Lansky >= 50 (less than 16 years of age)
ECOG 0, 1 or 2, or for children =< 10 years of age, Lansky >= 60
If <12 years of age: Lanksy Performance Status >50%
If ?12 years of age: Karnofsky Performance Status >50%
Karnofsky (age ? 16 years) or Lansky (age < 16 years) performance status ? 50 at screening
Karnofsky (age ? 16 years) or Lansky (age < 16 years) performance status ? 50 at screening.
Have an ECOG performance status of 0-2 for ? 16 years of age and a Lansky performance status of 70-100 for < 16 years of age
Karnofsky performance status (KPS) must be >= 70 for patients >= 16 years of age and Lansky performance status must be >= 70 for patients < 16 years of age
Must have a Lansky or Karnofsky performance status of >= 50; use Karnofsky for patients > 16 years of age and Lansky for patients =< 16 years of age
Patients must have a Lansky or Karnofsky performance status score of >= 60%; use Karnofsky for patients > 16 years of age and Lansky for patients =< 16 years of age
Age ?18 years (non-ESFT candidates) ECOG performance status (PS) 0-1. Pediatric patients with Lansky or Karnofsky Performance Status Scale ? of 50%.
Eastern Cooperative Oncology Group (ECOG) performance status =< 2 for adults, Karnofsky performance status >= 50% for pediatric patients > 10 years of age, and Lansky performance status >= 50 for pediatric patients =< 10 years of age
Karnofsky > 50% for patients > 16 years of age and Lansky > 50% for patients ? 16 years of age.
ECOG 0-2 or Karnofsky ? 50% for patients > 16 years of age; Lansky ? 50% for patients ?16 years of age.
Subjects < 16 years of age: Lansky scale ? 60% (Appendix A)
Karnofsky performance status > 70% for patients 16 years and older and Lansky performance status > 50% for patients under 16 years of age
Karnofsky > 50% for patients > 16 years of age and Lansky > 50% for patients less than or equal to 16 years of age. (See Appendix I for Performance Scales).
Performance Level: Karnofsky > 50% for pts > 12 years; Lansky > 50% for pts < 12 years of age.
Performance status: Karnofsky > 50% for >= 16 years of age; Lansky > 50% for children < 16 years of age
Performance status: Karnofsky >= 50 for > 10 years of age; Lansky >= 50 for children =< 10 years of age
Performance status: Karnofsky ? 60% for 12 to <18 years of age; Lansky play scale ? 60% for 1 to < 12 years of age.
Performance status - Karnofsky 50-100% (> 16 years of age)
Performance status - Lansky 30-100% (? 16 years of age)
Karnofsky performance status >= 50% for patients >= 16 years of age and Lansky >= 50% for patients < 16 years of age
Performance status must be > 60 from Lansky (age 1 to 16) or Karnofsky (age > 16)
Karnofsky >= 50% for patients > 10 years of age and Lansky >= 50 for patients =< 10 years of age
Performance status by Karnofsky of >= 70% or Lansky > 70% for patients < 16 years of age
ECOG 0-1, or for children ?10 years of age, Lansky > 60
Karnofsky performance status >= 50 for patients >= 12 years of age; for children < 12 years of age, the Lansky play scale >= 50% can be substituted
Karnofsky >= 70 for patients >= 16 years of age, and Lansky >= 70 for patients < 16 years of age
PHASE I: Performance status >= 60 on Karnofsky scale for patients > 16 years of age and > 60 on Lansky scale for patients < 16 years of age
EXPANSION COHORT: Performance status of >= 60 on Karnofsky scale for patients > 16 years of age and > 60 on Lansky scale for patients =< 16 years of age
Patients must have a performance status of >= 50 using the Karnofsky scale for patients > 16 years of age and the Lansky scale for patients =< 16 years of age
Karnofsky (patients ? 16 years)/Lansky (patients < 16 years) index ? 70.
Karnofsky performance status > 30% (given the aggressiveness of this disease and the often severely debilitated nature of the patients at initial presentation)
Premenopausal status
CRITERIA FOR MAINTENANCE THERAPY-STEP 4: Patients must have an ECOG performance status of 0-3
Patients must have a Karnofsky performance status >= 60% (i.e. the patient must be able to care for himself/herself with occasional help from others)
Disease status:
Performance status of Eastern Cooperative Oncology Group (ECOG) 0-2; patients with ECOG of 3 may be allowed to enroll after discussion with the regulatory-sponsor/principal investigator and medical monitor, and if the performance status is believed to be secondary to lymphoma related symptoms and performance status is expected to improve once chemotherapy commences
PIK3CA WILD TYPE COHORT (closed 03/17/2016): ECOG performance status of 0, 1 or 2
ENDOCRINE RESISTANT AND ADJUVANT COHORT: ECOG performance status of 0, 1 or 2
ECOG performance status 0-1 (appendix I) documented within 90 days prior to randomization.
EXPANDED ACCESS COHORT: ECOG performance status =< 2
Disease status requirement:
Disease status
Must have Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1, assessed within 14 days prior to randomization. Two observers qualified to perform assessment of the performance status will be required to perform this assessment. If discrepant, the one with the most deteriorated performance status will be considered true.
Patient has experienced a decline in ECOG performance status between Baseline visit and within 72 hours prior to randomization.
ECOG >2 performance status (Appendix A)
Eastern Cooperative Oncology Group (ECOG) performance status =< 2 (Karnofsky >= 60%) is required for eligibility; those patients with lower performance status based solely on bone pain secondary to multiple myeloma are eligible
Performance Status: ECOG 0, 1, and 2 (See Appendix III)
ECOG performance status 0-1 (appendix II) assessed within 90 days of randomization.
ARM I&II: Patients must have a Karnofsky performance status >= 70% (i.e. the patient must be able to care for himself/herself with occasional help from others)
ECOG performance status ? 2. (Patients with lower performance status based solely on bone pain secondary to multiple myeloma may be eligible following consultation and approval of the medical monitor)
Disease status as defined as.
COHORT 3: ENDOMETRIAL CANCER: ECOG performance status 0 or 1
Karnofsky performance status of ? 70 (able to take care of self)
Patients must have a Karnofsky performance status >= 60% (i.e. the patient must be able to care for himself/herself with occasional help from others)
Karnofsky performance status of ? 70 (able to care for self)
1p and 19q deletion status known
A specific performance status score is not required for enrolling on the protocol; a delay in infusion of the HA-1 TCR T cells may be required for patients with low performance status
Patients must have a Karnofsky performance status 60 or higher (i.e. the patient must be able to care for himself/herself with occasional help from others)
Adequate performance status (PS) as follows:\r\n* Patients >= 16 years must have Eastern Cooperative Oncology Group (ECOG) PS 0-1 and Karnofsky >= 60%\r\n* Pediatric patients < 16 years must have Lansky play-performance of 60\r\n** NOTE: Patients >= 16 years with an ECOG PS of 2 and Karnofsky >= 60 will be considered eligible at the discretion of the principal investigator if decreased ECOG performance status is felt to be related to residual neurologic deficits caused by CNS disease involvement that are not progressive or anticipated to cause clinical management problems during study participation
RAPID EXPANSION PROTOCOL (REP) ELIGIBILITY: Clinical performance status equivalent to ECOG 0-1 at the last calendar clinical visit
CHEMOTHERAPY/CELL INFUSION ELIGIBILITY: Clinical performance status equivalent to ECOG 0-1 at the clinical visit prior to lymphodepletion
Must have a Functional Performance Status of less than or equal to 2 on the ECOG scale (Appendix VII).
Eastern Cooperative Oncology Group (ECOG) performance status =< 3 (There may be certain patients with performance status [PS] 3 in the context of rapidly proliferative/refractory ALL who would benefit from this regimen. We don’t want to exclude such patients who may derive benefit from this salvage regimen)
Indeterminate or negative HER2 status
Patients with performance status of =< 3 (3 only allowed if decline in status is deemed related to\r\nlymphoma and felt potentially reversible by the treating physician)
JUST PRIOR TO FIRST VACCINATION (WITHIN 21 DAYS): ECOG performance status =< 2 (Karnofsky >= 60%)
Moribund status or status epilepticus
ECOG >2 performance status (Appendix D)
Performance status < 3, unless directly related to disease process as determined by the principal investigator
ADDITIONAL CRITERIA FOR STUDY CONTINUATION: ECOG performance 0-1
Known HER2 status
Patients must have a Karnofsky performance status of >= 60% at the time of the CD8+ memory T-cell infusion
Eastern Cooperative Oncology Group (ECOG) performance status (PS) =< 2; patients with a PS of 3 are eligible if the performance status is due to their malignancy, and not a co-morbid medical condition (example [ex]: perineal pain impacting their ability to sit or ambulate, etc.)
Patients with HER2(-) status
Patients with Eastern Cooperative Oncology Group (ECOG) performance status worse than 2 (ie unable to perform their own activities of daily living [ADLs] without assistance, unable to spend less than 50% of day out of bed)
Karnofsky performance status >= 70 in the 30 day baseline period immediately prior to dosing
Performance status =< 3, unless directly related to disease process as determined by the principal investigator
Patients must have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 (performance status of 2 will be allowed if poor performance status is thought to be directly secondary to patient’s Hodgkin lymphoma [HL])
Karnofsky performance status (PS) scores of 70 or greater
ECOG performance =< 2 at the time of second registration
ECOG performance status of ? 2 at study entry (see Appendix A).
Other Requirements\r\n* Patients must be able to give informed consent\r\n* Patients must have ECOG performance status 0, 1 or 2 and/or Karnofsky performance status (KPS) > 50\r\n* Patients must be able to swallow\r\n* Patients must be able to sit up with or without assistance\r\n* Patients must be able to undergo contrast-enhanced MRI (Cohort D)
Subject has a Karnofsky performance status ?60% (>50% if due to bony involvement of myeloma (see Appendix IV).
Adequate performance status (ECOG 0 or 1). (Appendix 1)
HER2 status negative
ECOG performance status 0-2 (Appendix 3)
Patients should have a performance status (Karnofsky score) of > 80 out of 100, i.e. can carry on normal activity with effort while showing some signs or symptoms of disease
Adequate performance status (ECOG 0 or 1) (Appendix 1)
Patients must have a Karnofsky performance status >= 60% (i.e. the patient must be able to care for himself/herself with occasional help from others)
ECOG performance status of 0 - 1 (Appendix C).
Patients must have a Karnofsky performance status >= 60% (i.e. the patient must be able to care for himself/herself with occasional help from others)
Eastern Cooperative Oncology Group (ECOG) performance status =< 2 (Karnofsky >= 60%)\r\n* Exception will be made for patients with ECOG performance status =< 3 and Karnofsky performance scale >= 50%, who require the use of wheelchairs, walkers or canes as well as assistance with daily routines secondary to disabilities caused by ECD cerebellar or brain disease that has been stable for >= 3 months
Recursive partitioning analysis (RPA) class I-II/Karnofsky performance status >= 70%
Eastern Cooperative Oncology Group (ECOG) performance status =< 2 (Karnofsky >= 60%) unless due to neurologic deficits caused by CNS lymphoma with the following exceptions: patients with ECOG performance status (PS) = 4 where neurologic deficits are unlikely to resolve with tumor resolution and may cause clinical management problems are excluded
Patients must have a Karnofsky performance status >= 60% (i.e. the patient must be able to care for himself/herself with occasional help from others)
Patients must have results from the determination of BAF250a immunohistochemistry (IHC) status and must have a BAF250a expression status that is currently open to enrollment
Clinical performance status equivalent to ECOG 0-1 at the clinical visit prior to apheresis
Karnofsky functional status rating >= 70
Lansky performance status ? 50% (children) or Karnofsky performance status ? 70% (adults) or ECOG performance status 0-2 (adults)
Patient has an ECOG performance status ? 2 (Patients with lower performance status based solely on bone pain secondary to multiple myeloma will be eligible)
Performance status with Eastern Cooperative Oncology Group (ECOG) score =< 2; patients with performance status of 3 may be considered as long as the decline has been of short duration (< 1 month), and is due to their malignancy and not a comorbid condition (example: pain limiting activity)
RB status
ECOG performance status >2 after optimization of analgesics
ECOG performance status of 0 or 1 (see Error! Reference source not found.).
Premenopausal status
Premenopausal status
Performance status < 3 (unless previous performance status was 0 or 1 and deterioration is due to lymphoma which treating medical doctor [MD] expects to reverse with therapy)
Have a Karnofsky performance status >= 70 (i.e. the patient must be able to care for himself/herself with occasional help from others)
ECOG performance status =< 2, unless the decline of the performance status is considered to be related to CLL symptoms
Participants must have a performance status of 0-2 based on Eastern Cooperative Oncology Group (ECOG) criteria; participants with a poor performance status (3-4) based solely on bone pain will be eligible, provided there is documentation to verify this
Eastern Cooperative Oncology Group (ECOG) performance status =< 2; patients with ECOG performance status of 3 (defined as being capable of only limited self-care, confined to bed or chair more than 50% of waking hours) will also be eligible only if the lower performance status is judged to be directly related to steroid and/or cGVHD effects
Pre-study ECOG performance status 0-2. Patients with lower performance status based solely on bone pain will be eligible.
Performance status must be Cancer and Leukemia Group B (CALGB) performance status (PS) 0, 1, or 2 (or Karnofsky 40-100%)
ECOG performance status of 0 or 1, measured at screening and immediately before the start of treatment.
Patients must have a Karnofsky performance status >= 60% (i.e. the patient must be able to care for himself/herself with occasional help from others)
ECOG performance status of 0 or 1 (see Appendix 8)
ECOG Performance status 0-1 (Appendix B)
Karnofsky performance status >= 70 (Radiation Therapy Oncology Group [RTOG] recursive partitioning analysis [RPA] class I & II)
Patients must have a Karnofsky performance status >= 60% (i.e. the patient must be able to care for himself/herself with occasional help from others)
ECOG PS (Eastern Cooperative Group Performance Status) of 0 or 1. 8. Ability to swallow oral capsules without difficulty. 9. Pregnancy Prevention Risk Management Plan:
Have an ECOG Performance Status of ? 1. Refer to Appendix 1.
Performance status of 0-2 based on the Eastern Cooperative Oncology Group (ECOG) criteria; patients with performance status 3 or 4, based solely on bone pain, are also eligible, provided that there is a source document to verify this
Eastern Cooperative Oncology Group (ECOG) performance status: 0 or 1. NOTE: Subjects with a performance status of 2 can be enrolled if the subject's confinement to bed and inability to carry out work activities is due solely to cancer-related pain, as assessed by the Investigator.
ECOG performance status of 0 or 1 (see Appendix C)
Low Performance Status (ECOG > 2; Appendix E).
ECOG performance status ? 1 (Karnofsky ? 70%; see Appendix B).
Patients must have a Karnofsky performance status >= 60% (i.e. the patient must be able to care for himself/herself with occasional help from others)
Performance score of >=50% according to the Karnofsky/Lansky performance status scale (subjects with a performance status of <=50% can be enrolled if the subject's confinement to bed and inability to carry out activities is due solely to cancer-related pain, as assessed by the investigator).
Recursive partitioning analysis (RPA) class I (Karnofsky performance status [KPS] >= 70%, primary cancer controlled, age < 65, metastases in brain only) or class II
Performance status of Eastern Cooperative Oncology Group (ECOG) =< 2 or Karnofsky >= 60%; note: participants with lower performance status based solely on bone pain secondary to multiple myeloma will be eligible
Patients with performance status of =< 3 (Eastern Cooperative Oncology Group performance status scale, 3 only allowed if decline in status is deemed related to lymphoma and felt potentially reversible by the treating physician)
There are no restrictions related to performance status or life expectancy
Patients with poor performance status preoperatively such that they are unable to walk up two flights of stairs
Karnofsky performance status >= 60 per COH SOP
Patients must have a Karnofsky performance status (KPS) >= 60% (i.e. the patient must be able to care for himself/herself with occasional help from others)
There are no restrictions related to performance status or life expectancy
Patients must have a Karnofsky performance status >= 60 % (i.e. the patient must be able to care for himself/herself with occasional help from others)
There are no restrictions related to performance status and life expectancy
Incarceration/ward of the state status
Poor preoperative performance status as defined by: timed get up and go (< 15 seconds)
PATIENT: Eastern Cooperative Oncology Group (ECOG) performance status of > 2 or Karnofsky performance status < 60 (suggesting patient is capable of only limited self-care, confined to bed or chair more than 50% of waking hours, or requires considerable assistance and frequent medical care) as rated by the attending oncologist
Karnofsky performance status >= 70 (Radiation Therapy Oncology Group [RTOG] recursive partitioning analysis [RPA] class I & II)
Have an Eastern Cooperative Oncology Group (ECOG) Performance Status of 0, 1, or 2. However, potential subjects with an ECOG of 3 may be enrolled provided their condition does not preclude performing the actions required by study participation (e.g., opening medication bottles, swishing the oral rinse and spitting out, completing or participating in completion of daily diaries and FACT-H&N forms).
CONTROL (HEALTHY) GROUP: ECOG performance status 0-1
Karnofsky performance status: Full intensity conditioning, 80-100%; reduced intensity conditioning, 60-100%
Patients must have a Karnofsky performance status >= 60% (i.e. the patient must be able to care for himself/herself with occasional help from others)
General performance status evaluated by ECOG 0-2 scale.
ECOG performance status of 0 to 2 (Appendix C)
Karnofsky performance status >= 70 with the ability to walk unassisted
The patient must have recovered from surgery with the incision completely healed and no signs of infection; if adjuvant chemotherapy was administered, chemotherapy-related toxicity that may interfere with delivery of radiation therapy should have resolved; the patient must have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 (Karnofsky performance status [KPS] > 70%)
Performance status: Lansky >= 50 for patients who are =< 16 years old and Karnofsky >= 50% for patients who are > 16 years old
Performance score using the Karnofsky performance scale (patients > 12 years old) or Lansky Play - performance scale (patients =< 12 years old) must be >= 60 assessed within two weeks prior to enrollment
Karnofsky >= 50% for patients > 16 years old, and Lansky >= 50 for patients 1-16 years old
Eastern Cooperative Oncology group (ECOG) =< 2 for patients >= 16 years old or Lansky play >= 60% for patients\r\n=< 15 years old
CELL PROCUREMENT: Karnofsky score > 60% if >= 16 years old or Lansky performance score of greater than 60% if < 16 years old
LYMPHODEPLETION: Karnofsky score > 60% if >= 16 years old or Lansky performance score of greater than 60% if < 16 years old
PRIOR TO CELL PROCUREMENT: Karnofsky or Lansky score of > 60% (Karnofsky for ? 16 years old and Lansky for < 16 years old)
PRIOR TO LYMPHODEPLETION: Karnofsky or Lansky score of > 60% (Karnofsky for pediatric patients ? 16 years old and Lansky for < 16 years old)
PRIOR TO INFUSION OF ATLCAR.CD30 CELLS: Karnofsky or Lansky score of > 60% (Karnofsky for ? 16 years old and Lansky for < 16 years old)
Performance status:\r\n* Lansky >= 50 for individuals 18 months- =< 16 years old; Karnofsky > 50% for individuals 17-21 years old
Patients must have a Lansky Play Scale of 60% (< 16 years [yrs] old), Karnofsky score 60% (> 16 yrs old), or Eastern Cooperative Oncology Group (ECOG) score of < or equal to 2 and a life expectancy of 2 months
Lansky performance status of >= 60% for participants 16 years old or younger
Patients 18 to =< 45 years: Karnofsky (>= 18 years old) >= 70 or Eastern Cooperative Oncology Group (ECOG) 0-1
Karnofsky (those 16 years old or older) or Lansky (those younger than 16 years) performance score of at least 50
Lansky score >50% for participants <16 years old.
Lansky Performance Status (participants less than [<] 16 years old) or Karnofsky Performance Status (participants greater than or equal to [>=] 16 years old) >=50
Performance status: Lansky >= 50 for patients who are =< 16 years old and Karnofsky >= 50% for patients who are > 16 years old
Performance status: Karnofsky or Lansky scores ? 50 for subjects > 16 years old or ? 16 years old, respectively.
Lansky (< 16 years old) >= 60
Performance status: Lansky >= 50 for individuals 18 months to < 10 years old; Karnofsky > 50% for individuals 10-21 years old
Karnofsky performance scale >= 12 years old (y/o) or Lansky performance score for patients < 12 y/o must be >= 50 assessed within two weeks prior to enrollment
Lansky >= 50 for patients =< 16 years old; Karnofsky >= 50 for patients > 16 years old
Performance status: Lansky >= 50 for patients who are =< 16 years old and Karnofsky >= 50% for patients who are > 16 years old
Karnofsky performance status >= 60% for patients > 16 years old (yo) and Lansky performance status >= 60% for patients =< 16 yo
Karnofsky performance status less than 60% or Lansky less than 40% for patients younger than 16 years old
Performance status: Lansky >= 50 for patients who are =< 16 years old and Karnofsky >= 50% for patients who are > 16 years old
Have a Karnofsky performance status greater than or equal to 50 for patients aged 16 years or older and a Lansky performance status greater than or equal to 50 for patients less than 16 years old
Age greater than or equal to (>/=) 18 years
Age greater than or equal to (>/=) 18 years
Age greater than or equal to 18 years
Age above or equal to 18 years
Patients must have a Karnofsky performance status of greater than or equal to 50 for patients older than 16 years of age or Lansky performance status of greater than or equal to 50 for patients less than or equal to 16 years of age.
Performance status: Karnofsky score greater than or equal to 70%. Additional Patient Inclusion Criteria for Conditioning:
Karnofsky equal or greater than 70
Be greater than or equal to (>=) 16 years of age at the time of consent.
Karnofsky performance status greater than or equal to 70%
Participants less than or equal to 16 years of age: Lansky greater than or equal to 50
Participants greater than 16 years of age: Karnofsky greater than or equal to 50 or Eastern Cooperative Oncology Group (ECOG) less than 3.
Lansky play score greater than or equal to 50% or Karnofsky Performance Status score greater than or equal to 50%. Use Karnofsky for participants greater than or equal to 16 years of age and Lansky for participants less than 16 years of age.
The ECOG performance status must be greater than or equal to 2.
Karnofsky greater than or equal to 80%
Patients with untreated AML must meet at least one of the following conditions:\r\n* Age greater than or equal to 75 years;\r\n* Age greater or equal to 60 and less than 75 years with at least one of the following poor prognostic factors:\r\n** Secondary AML, as determined by known and documented exposure to chemotherapy or radiation therapy\r\n** Antecedent history of MDS or myeloproliferative disorder according to WHO criteria for at least 3 months prior to trial entry;\r\n** Unfavorable cytogenetic abnormalities including chromosome 5 and 7 as well as complex;\r\n** ECOG performance status 2
Karnofsky performance status greater than or equal to 70%
Have a Karnofsky performance status greater than or equal to 50 for patients aged 16 years or older and a Lansky performance status greater than or equal to 50 for patients less than 16 years old
Performance status Lansky for children =< 16 years equal to at least 60, or greater Karnofsky status for those > 16 years of age equal to at least 70 or greater
Performance status (Eastern Cooperative Oncology Group [ECOG]) must be less than or equal to 2 (Karnofsky greater than or equal to 50)
Karnofsky performance status greater than or equal to 60%
Age greater than or equal to 15 years
Subjects must have Eastern Cooperative Oncology Group (ECOG) Performance Status of ) to 2 for subjects greater than or equal to 75 years of age, or 0 to 3 for subjects greater than or equal to 60 to 74 years of age
Age greater than or equal to (>=)18 years
Age greater than or equal to 18 years at the time of informed consent.
Age greater than or equal to 18 years.
Man or woman greater than or equal to (>=) 18 years of age
Zubrod performance status equal to or less than 2 (Karnofsky equal to or greater than 50%)
Subject must be greater than or equal to 65 years of age in Phase 1 and 2. Subjects enrolled in Cohort C must be either:
greater than or equal to 75 years of age; OR
of 0 to 2 for subjects greater than equal to 75 years of age
of 0 to 3 for subjects greater than equal to 60 to 74 years of age, if 0 - 1 another co-morbidity is required to make subject eligible.
Karnofsky Performance Status greater than or equal to 70%
Adult participants greater than or equal to 18 years of age
Subject must be greater than or equal to 18 years of age.
Age greater than or equal to 18 years, either sex.
Karnofsky performance status greater or equal to 70%
DONOR: Children greater than or equal to 12 years of age who have inadequate peripheral vein access to safely undergo apheresis
Patients must have a Karnofsky performance status equal or greater than 60.
Age greater than 55 years and less than or equal to 80 years (nonmyeloablative regimen 2)
Age greater than or equal to 18 years
Must be greater or equal to 20 years of age
International Prognostic Index (IPI) score greater than or equal to 3 for patients greater than 60 years of age or age-adjusted IPI (aaIPI) score of 2 or 3 for patients less than or equal to 60 years of age
Eastern Cooperative Oncology Group (ECOG) performance status less than or equal to 2 (Karnofsky greater than or equal to 60%)
Greater than or equal to 75 years of age
Ambulatory patients greater than or equal to (?) 30 years of age
Participants less than or equal to 16 years of age must have performance status of Lansky greater than or equal to 50% and participants greater than 16 years of age must have performance status of Karnofsky greater than 50%.
Age greater than or equal to 18 years.
Adult participants, greater than or equal to (>/=) 18 years of age
Karnofsky performance status greater than or equal to 80%
At US sites, patients greater than or equal to 12 years of age may be enrolled. At non-US sites, patients must be greater than or equal to 18 years of age.
Karnofsky performance status equal or greater than 50%
The minimum age from greater than 65, to greater than 55
The minimum age from greater than 55, to greater than 18
Australian Karnofsky performance status greater than or equal to 70 as reported by the patient
Individuals greater than or equal to 18 years of age
greater than or equal to 18 years of age
Age greater than or equal to 18 years, and
ECOG performance status greater than or equal to 2
Lansky or Karnofsky Score must be ? 50
Karnofsky scores < 60 or Lansky score < 50
Patients must have a Lansky (?16 years) or Karnofsky (> 16 years) score of at least 50
Karnofsky/Lansky performance score ? 60
TREATMENT: Patients with a Karnofsky/Lansky score of >= 50%
INCLUSION - TREATMENT: Karnofsky or Lansky score of > 60%
INCLUSION - INFUSION: Patients with a Karnofsky/Lansky score of ? 60
PROCUREMENT INCLUSION: Karnofsky or Lansky score of > 60%
TREATMENT INCLUSION: Karnofsky or Lansky score of > 60%
Participants with lansky-Karnofsky score of greater than or equal to (>=) 50
Patient may not have a Karnofsky performance score < 50% or Lansky performance score < 50%
Lansky score <50%
Karnofsky/Lansky score of ? 50
Karnofsky/Lansky score of ? 50
ELIGIBILITY CRITERIA AT TIME OF TREATMENT: Patients with a Karnofsky/Lansky score of ? 50
Patients with a Karnofsky/Lansky score of ? 50
Karnofsky/Lansky score ? 50%
INCLUSION - PROCUREMENT: Karnofsky/Lansky score of ? 50
INCLUSION - TREATMENT: Karnofsky/Lansky score of ? 50
Lansky or Karnofsky performance score >= 60
Karnofsky scores < 60 or Lansky score < 50
The patient must have a Lansky or Karnofsky performance score (KPS) of >= 70% at the time of entry
Karnofsky score (adults) < 60% or Lansky score < 50% (pediatrics)
Karnofsky score >= 70% (>= 16 years) or Lansky score >= 50 (< 16 years)
Karnofsky/Lansky score >= 60%
Lansky score <50%
Karnofsky or Lansky score of > 60%
Patients with a Karnofsky/Lansky score of >= 50
Karnofsky or Lansky score of > 60%
Lansky or Karnofsky score < 50%
Karnofsky/Lansky score >= 60%
Karnofsky/Lansky score of >= 50
Karnofsky/Lansky score of >= 50
Performance status score: Karnofsky (for adults) >= 60 or ECOG 0-2; Lansky (for children) score >= 50
Recipients must have a Karnofsky score (adults) >= 80 % or Lansky score >= 50% (pediatrics)
Patients must have a Lansky (?16 years) or Karnofsky (> 16 years) score of at least 50
Lansky (=< 10 years) or Karnofsky (> 10 years) score of at least 50
Karnofsky score >= 80% (adults), Lansky score >= 50% (pediatrics)
Lansky (=< 16 years) or Karnofsky (> 16 years) score of at least 50
Patients with a Karnofsky performance score < 70% or Lansky score < 70%
Karnofsky/Lansky score of 60% or greater
Patient with a Karnofsky performance score < 50% or Lansky score < 50%
Karnofsky/Lansky score of >= 50
Karnofsky/Lansky score of >= 50
Karnofsky/Lansky score of > 60%
Lansky/Karnofsky score > 50
Karnofsky score < 60 or Lansky score < 50
Karnofsky/Lansky score >= 50%
Karnofsky/Lansky score >= 50%
Karnofsky or Lansky score of > 60%
Lansky score < 60%
AT THE TIME OF INFUSION: Karnofsky or Lansky score of ? 50%
Karnofsky score >= 70 or Lansky score >= 70
Karnofsky or Lansky performance score of greater than or equal to 50
Karnofsky/Lansky performance score < 70%.
Karnofsky scores < 60 or Lansky Score < 50
Patients with a Karnofsky/Lansky score >= 50
Karnofsky performance score < 60 Lansky performance score < 60
Performance Score: Karnofsky ?60% if >10y/o, Lansky ?60 if ?10y/o
Karnofsky performance score (KPS) or Lansky score >= 40
Patients must have a Lansky (< 16 years) or Karnofsky (> 16 years) score of at least 50
Karnofsky or Lansky performance score is >= 60%; the Lansky performance score should be used for participants < 16 years and the Karnofsky performance score for participants >= 16 years
The presence of TAM high risk features at baseline (or screening if baseline visit is skipped): Patients ? 16 years must have a Lansky score of ? 70 and patients > 16 must have Karnofsky score ? 70% and/or proteinuria (> 30 mg/dL) measured in two urine spot analyses.
Subjects < 16 years: Lansky score ? 70%.
Adequate Karnofsky/Lansky Performance score
Karnofsky or Lansky performance score of greater than or equal to 50
Karnofsky or Lansky performance score is >= 60%; the Lansky performance score should be used for participants < 16 years and the Karnofsky performance score for participants >= 16 years
Karnofsky or Lansky performance score is >= 60%; the Lansky performance score should be used for participants < 16 years and the Karnofsky performance score for participants >= 16 years
Karnofsky or Lansky performance score >= 50
Karnofsky/Lansky score above 50%
Patients must have a Lansky or Karnofsky performance scale score of >= 50% and patients must have a life expectancy of >= 2 months
Lansky/Karnofsky score < 60
AYA is able to participate in sessions as evaluated by the Karnofsky/Lansky score of 50% or greater
Lansky score >= 50 for patients age < 16
Karnofsky/Lansky score of >= 50
Karnofsky or Lansky Performance Score < 70%
Patients must have a Lansky or Karnofsky Performance Scale score of > 50% and patients must have a life expectancy of ? 2 months.
Karnofsky or Lansky score of > 60%
Lansky score < 60%
Lansky score < 60%
Patients with a Karnofsky/Lansky score of >= 50
Lansky score ? 50 or
Karnofsky >= 60%,
Karnofsky >= 60%
Karnofsky >= 60%
Karnofsky >= 60%
ECOG > 2 (Karnofsky < 70%)
Karnofsky >= 60%
Karnofsky >= 60%
Karnofsky >= 60%
Karnofsky >= 60%
Karnofsky >= 70%
Karnofsky >= 60%
Karnofsky rating 70-100.
Karnofsky >= 70%
Karnofsky >= 70%
Karnofsky index >= 70%;
Karnofsky > 60%
Karnofsky >= 60% at time of screening
Karnofsky >= 80%
Karnofsky >= 60%
ECOG ? 2 OR Karnofsky ? 60%.
Karnofsky >= 70%
Karnofsky > 50%
Karnofsky >= 70%
Karnofsky >= 60%
Karnofsky >= 70%
Karnofsky > 70%
Karnofsky >= 70%
In poor health (Karnofsky <60%, ECOG >/-2)
Karnofsky >= 70%
In poor health (Karnofsky <60%, ECOG >2)
Karnofsky >= 60%